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ORIGINAL ARTICLES 
Department of Chemistry1, University of North Carolina, Ashville, and Division of Medicinal Chemistry and Natural Products2, 
School of Pharmacy, University of North Carolina, Chapel Hill, USA 
The cytotoxicity and mode of action of 2,3,4-trisubstltuted pyrroles and 
related derivatives in human Tmo14 leukemia cells 
J. T. GUPTON1, 8 . S. BUAHAM1, 8 . D. BYR01•2, K. E. KRUMPE1, C. STOKES1, J. SHUFORD1, S. WINKLE\ T. WEBB1, A. E. WARAEN2, 
C. R. 8AANEs2, J. HENRY2 and I. H. HALL2 
4-Carbechoxy-l-methyl-2-phenacyl-3-phenylpyrrole (9), 4-carbethoxy-2-(4-methoxybcnzoyl)-3-(4-methoxyphcnyl)pyrrole 
(10) and 2-(4-methoxybenzoyl)-3,4-bis-(4-methoxyphenyl)pyrrole (11) proved to be potent cytotoxic agents against the 
growth of murine and human leukemias and lymphomas. Selective· toxicity was demonstrated against the growth of solid 
tumors, e.g. human adenocarcinoma of the colon SW480 and ileum HCT-8, glioma U-87-MG, and rat UMR-106 osteo-
sarcoma. A mode of action study in Tmolt4 leukemia cells demonstrated that the agents inhibited de novo purine synth-
esis at the regulatory sites PRPP-amido transferase, IMP dehydrogenase as well as dihydrofolate reductase resulting in 
significant inhibition of DNA synthesis in 60 min. Other biochemical sites which were affected significantly were thymi-
dylate synthetase, DNA polymerase a, RNA polymerases, nucleoside kinase and ribonucleoside reductase. 
1. Introduction 
Recently we have been interested in vinylogous iminiurn 
salt based synthesis (1 - 41 of highly functionalized pyr-
roles and their applications to the synthetic modifications 
of marine natural product<; [5, 6] that contain such func-
tionality. The compounds included in this study have heen 
synthesized in this context and are structurally related to 
or are potential precursors or metabolites of these pyrrole 
containing marine natural products. Previously, two alkyl-
3,4-bis(4-methoxyphenyl)pyrrole-2-carboxylates proved to 
be potent cytotoxic agents in the murine Ll210 lymphoid 
leukemia screen r7J. DNA synthesis was preferentially in-
hibited with the major target of the agents being de novo 
purine biosynthesis at the regulatory enzyme sites of 
PRPP-amido transferase and ™P dehydrogenase. Other 
enzymatic activities which were suppressed marginally by 
the drugs were DNA polymerase a, RNA polymerases, 
ribonucleoside rcductase and dihydrofolate reductase. The 
DNA molecule itself was not the target of the agents, i.e. 
no alk.ylation of nucleotide bases, intercalation between 
bases or cross-linking of DNA strands occurred. The 
agents did cause LI 210 DNA fragmentation after 24 h in-
cubation at 100 µM. The present scudy involves a series of 
2-carboalkoxy-pyrroles or 2-phcnacyl pyrroles with diary! 
substitutions in positions 3 and 4 which are precursors or 
analogs of the marine natural products lukianol A and 
polycitone A. Also included is a series of 4-carbethoxy-2-
phenacyl-3-aryl pyrroles which are precursors of the mar-
ine natural product rigidin. 
2. Investigations and results 
The pyrrole derivatives demonstrated potent cytotoxicity 
against the growth of murine and human tumor cells (Ta-
ble 1). An ED50 value of less than 4 µg/ml is required for 
significant activity. In the mouse Ll2 IO lymphoid leuke-
mia screen all of the compounds were active with com-
pounds 2, 3, 5, 7, 9 and 11 producing the most potent 
ED50 values of < 2.00 µg/ml. ln the P388 lymphocytic leu-
kemia screen all of the compounds were active with com-
pound 7 producing a value of 1.18 µg/ml. In the human 
leukemic screens, i.e. Tmolt3, Tmolti and Jll-60, all of the 
compounds were active with compounds 2, 3, 5 , 6, 9 and 
11 having an ED5o value less than 2.00 µg/ml in the 
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Trnolt3 screen. Compounds 2 and 6 afforded ED50 values 
< 2.00 µg/ml in the Tmol4 screen and compounds 2, 3, 6, 
7 and IO were the most active in the Hl-60 screen. In the 
HuT-78 lymphoma screen all of the compounds were 
active with compound 10 afforiling an ED50 value of 
0. 93 ~ig/ml. In the THP- l monocytic leukemia screen all 
of the compounds were active with compound 4, 5, and 6 
producing a value of less than J µg/ml. ln the HeLa-S3 
uterine suspended carcinoma compounds 3, 4 , 6, 9 and IO 
afforded values <3.00 µg/ml. Jn the KB nasopharynx 
screen only compound 8 was active. Growth of adenocar-
cinoma of the SW480 colon was reduced significantly by 
compounds 4, S, 6, 8, and 9, and of adenocarcinoma of 
the ileum HCT-8 was suppressed by compounds 7, 8, 
9, 10 and 11. Lung A549 growth wa.<; reduced only by 
compounds 7, 8, and 10. Glioma U-87-MG growth was 
reduced by compounds 3 and 11. None of the compounds 
were active against the growth of lung MB9812, solid 
HeLa uterine carcinoma, and melanoma. ln the rat UMR-
106 osteosarcoma screen compounds 3, 7, 8, 9, and 11 
demonstrated potent activity with ED5<1 values of 
< 2.00 µg/ml. 
In the mode of action study in human Tmolt4 leukemia 
cells both compounds 9 and IO demonstrated preferential 
inhibition of DNA synthesis in a concentration dependent 
manner over 60 min resulting in 93% and 66% reduction, 
respectively at 100 µM (Tables 2-4). 
Compound 11 bad less effects with 46% reduction after 
60 min. RNA synthesis was inhibited, i.e. 21 % by com-
pound 10, 54% by compound 9 and 75% by compound 
11 at 100 µM and protein synthesis was not significantly 
affected by compounds 9 and 10 but 11 caused 40% re-
duction over 60 min. DNA polymerase u activity was sup-
pressed 32% by compound 11, 44% by compound 9 and 
55% by compound 10. mRNA polymerase activity was 
inhibited 44% by compound 10, 36% by compound 11 
and 32% by compound 9. r-RNA polymerase activity was 
reduced 33% by compound 9 and 58% by compound 10 
while t-RNA polymerase activity was inhibited 61% by 
compound 10 and 19% by compound 11. Ribonudeoside 
reductase activity was suppressed 28% and 32% by com-
pounds 9 and 10 and dihydrofolate reductasc activity was 
reduced 7 1 % and 78% by the compounds 9 and 10 but 
compound 11 caused only 32% reduction at 100 µMover 
60 min. De novo purine synthesis was suppressed 24% by 
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Table 1: Cytotoxicity of 2,3,4-trisubstituted pyrroles and related derivatives (ED50 = µg/ml, N = 6) 
Compd. Ll210 P388 Tmolt3 Tmolt., Hl-60 HuT-78 THP-1 HeLa-S3 KB Naso- Colon Lung A549 
Leukemia Leukemia Leukemia Leukemia Leukemia Lymphoma Acute uterine pharynx SW 480 
monocytic 
1 2.73 3.37 4.31 3.61 2.25 2.96 2.25 5.12 5.23 7.26 7.35 
2 1.51 2.87 1.47 1.58 1.46 2.32 1.12 4.18 6.92 5.26 4.46 
3 1.41 3.04 1.59 2.14 1.01 1.68 1.56 2.94 7.05 7.67 4.41 
4 3.39 1.95 2.24 3.88 3.04 1.42 0.81 2.69 6.16 3.28 4.81 
5 1.79 2.81 1.07 2.61 2.03 2.71 0.75 3.58 6.69 3.52 5.24 
6 3.76 2.99 1.20 1.43 1.01 1.41 0.62 2.56 7.95 3.56 5.13 
7 1.41 1.18 4.22 4.59 1.91 2.06 1.19 4.99 4.60 5.31 3.53 
8 2.39 1.89 3.7 3.41 2.25 2.96 1.75 4.99 2.87 3.42 3.67 
9 1.6 3.4 1.98 4.97 2.25 2.06 1.69 2.42 4.36 2.09 5.92 
10 2.10 3.61 2.18 2.04 1.58 0.93 1.25 2.43 6.68 5.25 2.88 
11 1.84 2.40 1.19 2.06 2.25 1.42 2.63 3.46 4.69 7.09 4.16 
std 
6-MP 2.43 2.04 0.43 2.67 6.36 1.63 3.34 2.12 5.74 3.61 4.71 
Ara-C 2.07 0.79 1.29 2.36 3.90 2.50 2.54 2.13 2.84 3.42 5.62 
HU 2.67 1.30 4.47 6.68 5.22 3.87 1.96 5.27 7.33 8.89 
5-FU 1.41 0.99 2.14 2.75 5.28 1.50 0.49 2.21 1.25 2.47 3.58 
VP-16 1.83 0.99 1.00 1.92 3.49 1.13 3.27 1.89 3.32 0.93 4.74 
CH30 OCH3 CH30 
CH30 
0-......../ N N 
O,CH3 
02? 
0 ~ 0 0 2 
OCH3 OCH3 
CH30 
CH30 OCH3 
CH30 
0 0 
0 
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0 
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0 0 
0 
7 9 
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Lung HeLa solid Melanoma HCT-8 UMR-106 Glioma 
MB uterine Sk-2 Ileum bone U-87-MG 
9812 
6.13 6.56 8.47 4.32 2.05 5.92 
7.32 9.01 6.94 8.81 10.14 4.16 
5.95 6.40 8.65 4.67 0.39 3.40 
8.85 10.56 10.01 5.72 7.53 4.83 
7.51 7.62 7.43 8.31 9.55 4.31 
6.83 7.73 10.01 9.88 8.95 4.82 
6.60 4.64 8.12 2.51 1.57 7.46 
4.81 6.34 8.12 2.34 0.86 7.51 
5.09 6.72 7.6 2.51 1.54 4.90 
8.75 8.91 8.61 3.7 3.36 7.03 
7.67 7.36 8.00 3.85 0.63 3.40 
4.29 5.61 6.86 1.15 9.13 4.46 
6.16 4.74 10.53 2.54 0.86 1.88 
7.18 8.12 1.77 2.87 2.27 
5.07 4.11 5.93 1.12 3.52 1.28 
3.50 3.05 3.53 3.78 3.57 2.44 
compound 10, 42% by compound 9 and 48% by com-
pound 11 at 100 µM while the activity of the regulatory 
enzymes of this pathway were also inhibited, i.e. PRPP-
amido transferase activity 48% by compound 10 and 63% 
by compound 9 while IMP dehydrogenase activity 35% 
by compound 10 and 72% to 73% by compounds 9 and 
11 over 60 min. De novo pyrimidine synthesis after 
60 min incubation at 100 µM by compound 9 was inhib-
ited 37%. The activity of the early regulatory enzymes of 
the pathway were not affected by the agents except aspar-
tate transcarbamylase activity was reduced 24% at 100 µM 
by compound 11. Thymidylate synthetase activity over 
60 min at 100 µM was suppressed 62% by compound 9 
and 81 % by compound 10. Thymidine kinase activity was 
reduced 25% by compound 9 and 39% by compound 10 
but elevated 110% by compound 11. TMP and TDP ki-
nase activities were inhibited 24% and 60%, respectively 
by compound 10 at 100 µM over 60 min. Compound 11 
elevated TMP kinase activity 99% after 60 min. Com-
pound 10 lowered the pool levels of d[GTP] by 77% and 
d[TTP] by 82% and compound 9 lowered d[TTP] pool 
levels by 71 % after 60 min incubation at 100 µM. Com-
pound 11 lowered d[ATP] pools 27%, d[GTP] pools 54% 
and d[TTP] pools 24% at 100 µM. 
Calf-thymus DNA studies demonstrated that the UV ab-
sorption from 220 to 340 nm was not affected by com-
pounds 9 and 10 whereas compound 11 causes a hyper-
chromic shift to a higher wavelength. ct-DNA denaturation 
studies showed that the control Tm value was 85 °C while 
compound 11 was 77.5 °C, compound 10 was 72.5 °C 
and compound 9 was 45 °C. ct-DNA viscosity for the con-
trol was 607 s whereas compound 10 was 345 s, com-
pound 9 was 601 s and compound 11 was 608 s. Tmol4 
DNA fragmentation studies after 24 h incubation at 
100 µM showed that compounds 10 and 11 caused DNA 
strand scission (Fig., low molecular weight) but compound 
9 appears to cause cross-linking of DNA since a higher 
percentage of radioactivity appeared at fraction number l 7 
(the highest molecular weight). 
3. Discussion 
2,3,4-Trisubstituted pyrroles proved to be potent cytotoxic-
ity agents suppressing the growth of suspended cells, e.g. 
murine Ll210 and P388 leukemia cells, human Tmolt3, 
Tmol4 and Hl-60 leukemia, Hut-78 lymphomas, THP-1 
monocytic leukemia, and suspended HeLa uterine carcino-
ma. More selectivity was demonstrated by the compounds 
against the growth of tissue cultured cells derived from 
solid tumors. Selected compounds were active against hu-
man KB nasopharynx, SW480 colon, lung A549, HCT-8 
ileum, glioma U-87-MG and rat UMR-106 osteosarcoma 
Table 2: Effects of compound 9 on Tmolt, leukemia cell metabolism over 60 min 
[N=4] Control Percent of control (X ± S.D.) 
25µM 50µM IOOµM 
Assay 
DNA synthesis 100 ± 5a 17 ± 3* 8 ± 2* 7 ± 2* 
RNA synthesis 100 ± 6b 51±4* 46±4* 46 ± 5* 
Protein synthesis 100 ± 5c 99±6 86 ± 5 86±6 
DNA polymerase alpha 100 ± 4ct 126 ± 7 112 ± 5 56 ±4* 
mRNA polymerase 100 ± 7e 156 ± 6 84±5 68 ±4* 
rRNA polymerase 100 ± 4f 79 ±6 68 ±4* 67 ±4* 
tRNA polymerase 100 ± 7g 103 ± 8 87 ± 5 85 ± 6 
Ribonucleoside reductase 100 ± 5h 86 ± 6 78 ± 5* 72±4* 
Dihydrofolate reductase 100 ± 5i 52 ±4* 49 ± 3* 22 ± 3* 
Purine de nova synthesis 100 ± si 70 ± 4* 62 ± 5* 58 ±4* 
PRPP amido transferase 100 ± 6k 96±6 63 ± 5* 37 ±4* 
INIP dehydrogenase 100 ± 51 71±4* 52 ±4* 27 ± 2* 
Pyrimidine de nova synthesis 100 ± 6m 90±5 82±4 63 ±4* 
Carbamyl phosphate synthetase 100 ± 7n 120 ± 6 116 ± 5 115 ± 6 
Aspartate transcarbamylase 100 ± 6° 100 ± 5 99 ±5 99 ±6 
Thymidylate synthetase 100 ±SP 85 ± 5 69 ±4* 38 ±4* 
Thymidine kinase 100 ± 6q 139 ± 7* 109 ± 6 76 ±4* 
Thymidine monophosphate kinase 100 ± 7r 248 ± 8* 238 ± 7* 113 ± 6 
Thymidine diphosphate kinase 100 ± 6s 128 ± 6 143 ± 7* 96±5 
d[ATP] 100 ± 5t 109 ± 5 
d[GTP] 100 ± 6u 91 ±4 
d[CTP] 100 ± sv 106±4 
d[TTP] 100 ± 4w 29 ± 4* 
Control values for 106 cells/h 
'12719dpm, b 11261 dpm,' 14382dpm, d 6090dpm,' 2341 dpm, r 673dpm, g 874dpm, h 56734dpm, i 0.1980.D. units, i 27621 dpm, k 0.12360.D. units, 1 15578dpm, 
units, m 17342 dpm," 0.912 mo! N-carbamyl spartate, 0 0.456 mmol citrulline, P 657642 dpm, q 2345 dpm,' 346579 dpm,' 2674 dpm,' 17.23 pmol," 16.38 omol,' 23.45 pmol, 
• 18.14 pmol, * P = 0.001 Student's "t" test 
Pharmazie 54 (1999) 9 693 
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Table 3: Effects of compound 10 on Tmolti leukemia cell metabolism over 60 min 
[N=4] Control 
Assay 
DNA synthesis 100 ± 5 
RNA synthesis 100±6 
Protein synthesis 100 ± 5 
DNA polymerase alpha 100±4 
mRNA polymerase 100 ± 7 
rRNA polymerase 100 ±4 
tRNA polymerase 100 ± 7 
Ribonucleoside reductase 100± 5 
Dihydrofolate reductase 100 ± 5 
Purine de nova synthesis 100± 5 
PRPP amido transferase 100±6 
~p dehydrogenase 100± 5 
Pyrimidine de nova synthesis 100 ± 6 
Carbamyl phosphate synthetase 100 ± 7 
Aspartate transcarbamy lase 100 ± 6 
Thymidylate synthetase 100 ± 5 
Thymidine kinase 100± 6 
Thymidine monphosphate kinase 100 ± 7 
Thymidine diphosphate kinase 100±6 
d[ATP] 100 ± 5 
d[GTP] 100± 6 
d[CTP] 100 ± 5 
d[TTP] 100±4 
growth. None of the compounds were active against the 
growth of lung MB9812, solid HeLa, or melanoma. The 
pattern of cytotoxicity demonstrated by these compounds 
is similar to known clinical antineoplastic agents which 
are metabolic inhibitors. A mode of action study in human 
Tmol4 leukemia cells demonstrated that the agents prefer-
entially inhibited DNA synthesis after 60 min incubation 
followed by the suppression of RNA synthesis. Protein 
synthesis was not affected by the agents except by com-
pound 11 over 60 min at these concentrations. Examina-
tion of sites within the nucleic acid pathway where the 
Percent of control (X ± S.D.) 
25µM 50µM lOOµM 
66 ±4* 61±3* 34 ± 3* 
145 ± 5* 83 ± 5 79 ±4* 
119 ± 6 114 ± 5 90±5 
105 ± 5 76 ±4* 45 ±4* 
101±6 61±5* 56 ±4* 
50± 5* 46±4* 42 ±4* 
87 ±6 59 ± 5* 39 ±4* 
82 ± 5 75 ±4* 68 ±4* 
57 ± 3* 30± 2* 29 ± 3* 
109 ± 5 84 ± 5 76 ±4* 
84 ± 5 83 ±4 52 ± 3* 
80±4 65 ± 4* 65 ± 3* 
111±7 103 ± 6 95 ± 5 
90±6 89 ± 5 83 ±5 
100±5 100 ± 6 89 ± 6 
91±5 82±4 19 ± 2* 
131±5 81±4* 61±3* 
94±5 93 ± 5 75 ±4* 
78 ±4* 52 ±4* 40 ± 3* 
108 ±6 
23 ± 3* 
112 ± 6 
18 ± 4* 
agents had their major effects appeared to be DNA poly-
merase a, dihydrofolate reductase, purine de nova synth-
esis and thymidylate synthetase. Reduction by the agents 
of all of these enzyme reactions would add to the overall 
suppression of DNA synthesis. The inhibition by the 
agents of the activities of the two regulatory enzyme of 
purine synthesis, i.e. PRPP-amido transferase and IMP de-
hydrogenase in a concentration dependent manner would 
lead to lower nucleotides for RNA and DNA synthesis but 
the suppression would appear in DNA synthesis quicker 
than RNA since the ratio of RNA to DNA pools in mam-
Table 4: Effects of compound 11 on Tmolti leukemia cell metabolism over 60 min 
[N=4] 
Assay 
DNA synthesis 
RNA synthesis 
Protein synthesis 
DNA polymerase a 
mRNA polymerase 
rRNA polymerase 
tRNA polymerase 
Ribonucleoside reductase 
Dihydrofolate reductase 
Purine de novo synthesis 
PRPP amido transferase 
IMP dehydrogenase 
Pyrimidine de novo synthesis 
Carbamyl phosphate synthetase 
Aspartate transcarbamylase 
Thymidylate synthetase 
Thymidine kinase 
Thymidine monphosphate kinase 
Thymidine diphosphate kinase 
d[ATP] 
d[GTP] 
d[CTP] 
d[TTP] 
694 
Control 
100±5 
100 ± 6 
100±5 
100 ± 6 
100±7 
100 ±4 
100 ±7 
100 ± 5 
100±5 
100 ± 5 
.100 ± 6 
100 ± 5 
100 ± 5 
100 ± 8 
100 ± 6 
100 ± 5 
100±6 
100 ± 7 
100±6 
100 ± 5 
100±6 
100 ± 5 
100±4 
Percent of control (X ± S.D.) 
25 µM 
88 ± 5 
53 ± 3* 
132 ± 6* 
72 ±4* 
85 ± 5 
94±5 
103 ± 4 
125 ± 6 
126 ± 6 
70± 3* 
105 ± 5 
55 ± 5* 
107 ± 4 
116 ± 4 
112 ± 5 
139 ± 7* 
149 ± 6* 
120 ± 6 
153 ± 5* 
SOµM 
66±5 
30 ± 2* 
98 ± 5 
70 ± 5* 
76 ±4* 
94±4 
81±5 
93 ± 5 
112 ± 5 
61±4* 
94±4 
44 ± 3* 
97 ±4 
115 ± 5 
98 ±6 
118 ± 4 
202 ± 7* 
144 ± 5* 
113 ± 4 
lOOµM 
54 ±4* 
25 ±4* 
60 ± 4* 
68 ±4* 
64 ± 4* 
84±5 
81±4* 
86±4 
68 ± 4* 
52 ± 3* 
88 ±4 
28 ± 3* 
93 ± 5 
85 ± 5 
76 ± 4* 
94±5 
210 ± 6* 
199 ± 6* 
82 ± 5 
73 ±4* 
46 ± 5* 
96 ± 5 
76 ±4* 
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malian cells is 90: 10 [34]. The suppression of dihydrofo-
late reductase activity afforded by the compounds would 
cause suppression of one-carbon transfer required for pur-
ine synthesis. Reduction of thymidylate synthetase activity 
caused by the agents would lead ultimately to reduced 
TIP pool levels for incorporation into DNA. Interestingly 
these reduced pool levels were evident after 60 min. Other 
marginal effects of the agents were on ribonucleoside re-
ductase activity which would lower the levels of deoxy-
ribonucleotides for incorporation into the new strand of 
DNA. In addition, RNA synthesis was probably sup-
pressed due to the inhibitory effects of the agents on RNA 
polymerase activities over 60 min. 
4-Carbethoxy- 2-( 4' -methoxybenzoyl)-3 - ( 4' -methoxyphe-
nyl)pyrrole (10) appeared to have some additional effects 
on nucleic acid metabolism in that thymidine, TMP and 
TDP kinase activities were suppressed. 4-Carbethoxy-
l-methyl-2-phenacyl-3-phenylpyrrole (9) suppressed only 
thymidine kinase activity but was more effective in block-
ing de novo pyrimidine synthesis. Thus, the substitution of 
different functional groups on the aromatic rings and the 
nitrogen of the pyrrole do make some difference in their 
effects on enzymes of nucleic acid metabolism. 
ct-DNA studies suggested that the agents did not cause 
akylation of the bases of DNA since there was no hyper-
chromic shift of the absorption of DNA except with com-
pound 11. On the other hand, reduction in ct-DNA viscos-
ity and Tmolti DNA strand scission by compound 10 
suggest this agent caused DNA fragmentation after 24 h. 
Conversely compound 9 increased ct-DNA viscosity and 
probably caused cross-linking of the two strands of DNA. 
The changes in the Tm value with compound 9 suggest a 
reaction with the DNA molecule also. At first these effects 
of the two agents on ct-DNA appear different from each 
other. One explanation may be that the compounds inter-
act with DNA in a deleterious manner which is not stable 
and that compound 10 causes DNA fragmentation quicker 
than compound 9. More detailed studies are required to 
address this effect of the agents. 
In conclusion, these pyrroles offer a new chemical series 
of compounds which may be explored in the future as 
antineoplastic agents to be used in combination chemo-
therapy or in resistant cancer cells. They demonstrate a 
therapeutic profile which is very similar to current clini-
cally used antineoplastic agents. 
Pharmazie 54 (1999) 9 
4. Experimental 
4.1. Materials and apparatus 
The following procedures are typical of the experimental conditions used 
for the reaction of vinylogous iminium salts and other three-carbon syn-
thons with a-amino carbonyl compounds. The vinylogous iminium salts 
and ~-chloroenals were prepared by standard methods [1-4]. All purified 
compounds gave a single spot upon TLC analysis on silica gel 7GF eluted 
with ethyl acetate/hexane mixture (30: 70), respectively. Distillations were 
carried out on an Aldridge Kugelrohr apparatus at reduced pressure. Chro-
matographic separations were carried out on a Harrison Chromatotron 
using silica gel plates of 2 mm thickness with a fluorescent backing or by 
standard column chromatography techniques. IR spectra were recorded on 
a Perkin-Elmer-1600 FTIR and NMR spectra were obtained with a Varian 
Gemini 200 spectrometer. All samples gave 13C NMR spectra consistent 
with a sample purity in excess of 98%. All melting and boiling points are 
uncorrected. High resolution MS were obtained by Midwest Center for 
Mass Spectrometry at the University of Nebraska-Lincoln. The following 
compounds were synthesized by previously published methods: 2-car-
bethoxy-4-(4-methoxyphenyl)pyrrole (1) [l], lamellarin-0-dimethyl ether 
(2) [5], and 2-carbethoxy-3,4-diphenylpyrrole (5) [4]. 
4.2. Synthesis 
4.2. I. N-(4' -Methoxyphenethyl-2-oxo )-4-(4' -methoxyphenyl)-2-carbethoxy 
pyrrole (3) 
Previously reported methods [1,5] were used to prepare compound 3. This 
compound exhibited the following properties: m.p. 154-155 °C; 1H NMR 
(CDC13) o 3.74 (s, 3H), 3.81 (s, 3H), 3.88 (s, 3H), 5.72 (s, 2H), 6.88 (d, 
J = 8.8 Hz, 2H), 6.96 (d, J = 8.8 Hz, 2H), 7.20 (d, J = 1.8 Hz, 1 H), 7.25 
(d, J = 1.8 Hz, 1 H), 7.44 (d, J = 8.8 Hz, 2H), 7.98 (d, J = 8.8 Hz, 2H); 
13C NMR (CDC13) o 51.3, 54.9, 55.4, 55.7, 114.3, 115.3, 122.9, 124.7, 
126.2, 126.6, 127.4, 128.1, 130.5, 158.4, 162.0, 164.3, and 191.9; IR 
(KBr) 1600 cm-1; MS (FAB) calcd. 380.1497, found 380.1535 (M + H). 
C22H21NOs 
4.2.2. 2-Carbethoxy-4-(41-methoxyphenyl)-5-(4' -methoxybenzoyl)pyrrole 
(4) 
To a solution of 3.13 g (20.57 mmol) of 4-methoxybenzoic acid in 25 ml 
dry methylene chloride was added 4.32 g (20.57 mmol) of trifluoroacetic 
anhydride. The resulting solution was stirred for 15-20 min at room tem-
perature followed by the addition of 5.48 g (48.02 mmol) of trifluoroacetic 
acid and then stirred for 5 min at room temperature. Subsequently, 1.68 g 
(6.86 mmol) of 2-carbethoxy-4-(4'-methoxyphenyl)-pyrrole was added 
upon which the solution darkened immediately. This solution was then 
stirred at room temperature for 3 d and the reaction was quenched by the 
addition of sodium hydroxide pellets followed by stirring overnight at 
room temperature. The mixture was transferred to a separatory funnel 
where it was partitioned between chloroform and water (3 x 150 ml). The 
combined chloroform layers were dried over anh. magnesium sulfate, fil-
tered and concentrated. The crude residue was found to be pure enough to 
be subjected to radial chromatography using hexane 90: 10 hexane/ethyl 
acetate, followed by 80: 20 hexane/ethyl acetate as eluant. After removal 
of the solvent, 2.45 g (6.47 mmol, 94.3%) of brownish orange crystals (4) 
were obtained. Compound 4 had the following properties: m.p. 145-
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147 °C; 1H NMR (CDCl3) 6 1.39 (t, J = 7.1 Hz, 3 H), 3.73 (s, 3 H), 3.75 
(s, 3H), 4.39 (q, J=7.1Hz, 2H), 6.63 (d, J=8.9Hz, 2H), 6.66 (d, 
J = 8.9 Hz, 2H), 6.99 (d, J = 2.9 Hz, I H), 7.06 (d, J = 8.9 Hz, 2H), 7.54 
(d, J = 8.9 Hz, 2 H) and 9.86 (bs, I H); 1H NMR (DMSO-d6) 6 1.39 (t, 
J = 7.1 Hz, 3H), 3.7 (s, 3H), 3.8 (s, 3H), 4.3 (q, J = 7.1 Hz, 2H), 6.76 
(d, J = 8.9 Hz, 2H), 6.89 (d, J = 8.9 Hz, 2H), 6.99 (d, J = 2.6 Hz, I H), 
7.16 (d, J = 8.9 Hz, 2H), 7.62 (d, J = 8.9 Hz, 2H), 12.5 (bs, I H); 
13CNMR (CDCh) 6 16.4, 31.7, 57.2, 57.3, 63.1, 115.1, 115.5, 118.1, 
127.5, 129.1, 131.5, 131.6, 132.5, 133.7, 134.1, 160.6, 162.4, 164.9 and 
188.1; IR (KBr) 3309, 2970, 1711, 1597, 1453 and 1175cm-1; HRMS 
(EI) calcd. 379.1420, found 379.1421. 
C22H21NOs 
4.2.3. 2-Carbethoxy-3,4-bis(41-methoxyphenyl)pyrrole ( 6) 
This compound was prepared in an analogous manner to compound S [4]. 
This compound exhibited the following properties: m.p. 119-123 °C; 1H 
NMR (CDC13) 6 1.18 (t, J = 7 Hz, 3 H), 3.76 (s, 3 H), 3.81 (s, 3 H), 4.20 
(q, J = 7 Hz, 2 H), 6.75 (d, J = 8 Hz, 2H), 6.84 (d, J = 8 Hz, 2H), 7.00-
7.06 (m, 3H), 7.20 (d, J=8Hz, 2H) and 9.30 (broads, lH); 13C NMR 
(CDC13) 6 14.29, 55.32, 60.29, 113.19, 113.86, 119.96, 120.05, 126.63, 
126.79, 127.36, 129.12, 129.67, 132.19, 158.25, 158.77 and 161.44; 
IR (KBr) 3300 and 1675 cm-1; HRMS calcd. 351.1471, found 351.1443. 
C21H21N04 
4.2.4. 3,4-Diphenyl-2-phenacylpyrrole (7) 
This compound was prepared in a manner analogous to the previously 
reported procedure [4] with the exception that a-arninoacetophenone hy-
drochloride was used in the place of glycine ethyl ester in the reaction. 
The purified product exhibited the following physical properties: m.p. 
178-179 °C; 1H NMR (CDC13) 6 6.80-7.30 (m, 14H), 7.38 (d, 
J= 8.0Hz, 2H) and 9.68 (br. s, IH); 13C NMR (CDC13) 6 125.1, 128.2, 
128.5, 128.7, 128.8, 129.4, 129.6, 130.2, 130.4, 130.6, 131.1, 131.9, 
132.7, 132.8, 133.0, 133.2, 136.1, 136.2, 136.4, 136.5, 139.8, 139.9 and 
189.9; IR (CC14) 3446, 3283, 1602, 1544 and 1385 cm- 1; HRMS (EI) 
calcd. 323.1310, found 323.1297. 
C23H11NO 
4.2.5. 4-Carbethoxy-2-phenacyl-3-phenylpyrrole (8) 
This compound was prepared in a manner analogous to a previously reported 
procedure [4] with the exception the a-aminoacetophenone hydrochloride 
was used in place of glycine ethyl ester in the reaction. The purified product 
exhibited the following physical properties: m.p. 141-142 °C; 1H NMR 
(DMSO-d6) 61.11(t,J=7.1Hz,3H), 4.06 (q,J = 7.1Hz,2H),7.00-7.18 
(m, 7 H), 7.2-7.40 (m, 3 H), 7.73 (d of d, J = 3.5 Hz and 1.3 Hz, I H) and 
12.58 (br. s, I H); 13C NMR (CDCl3) 6 16.2, 62.0, 118.9, 129.0, 129.1, 
129.4, 130.8, 130.9, 131.7, 133.1, 133.4, 135.0, 135.4, 139.1, 165.9 and 
190.0; IR (CC14) 3246, 1718 and 1610cm-1; HRMS (El) calcd. 319.1208, 
found 319.1194. 
C20H11N03 
4.2.6. 4-Carbethoxy-l-methyl-2-phenacyl-3-phenylpyrrole (9) 
This compound was prepared by the reaction of 4-carbethoxy-2-phenacyl-
3-phenylpyrrole with iodomethane, sodium hydride in DMF in a manner 
previously reported [4]. A 100% crude yield was obtained and a 98% pur-
ified yield of a light yellow solid resulted after purification by radial chro-
matography. The purified product exhibited the following properties: m.p. 
146-147°C; 1H NMR (DMSO-d6) 6 1.13 (t, J=7.1Hz, 3H), 3.85 
(s, 3H), 4.08 (q, J = 7.1 Hz, 2H), 6.96-7.18 (m, 7H), 7.30 (t, J= 7.2Hz, 
I H), 7.42 (d of d, J = 7.0 Hz and 1.2 Hz, 2H) and 7.91 (s, I H); 
13C NMR (CDC13) 6 16.2, 39.3, 61.8, 115.4, 128.9, 129.5, 131.6, 132.2, 
133.1, 133.9, 135.3, 135.7, 140.1, 165.8 and 191.0; IR (CC14) 3065, 2958, 
1706, 1632 and 1252cm-1; HRMS (EI) calcd. 333.1365, found 333.1353. 
C21H19N03 
4.2. 7. 4-Carbethoxy-2-(41-methoxybenzoyl)-3-(4' -methoxyphenyl)pyrrole 
(10) 
This compound was prepared in a manner analogous to compound 8. The 
purified product exhibited the following properties: m.p. 151-152 °C; 
1H NMR (CDC13) 6 1.21 (t, J = 7.1 Hz, 3 H), 3.70 (s, 3 H), 3.72 (s, 3 H), 
4.17 (q, J=7.I Hz, 2H), 6.52 (d, J=9.0Hz, 2H), 6.60 (d, J=9.0Hz, 
2H), 7.02 (d, J=9Hz, 2H), 7.37 (d, J=9.0Hz, 2H), 7.72 (d, J=3Hz, 
I H) and 10.20 (broad s, I HJ; 13C NMR (CDC13) 6 14.4, 55.3, 55.4, 60.0, 
112.9, 113.0, 116.6, 125.8, 128.6, 129.8, 130.1, 131.7, 132.6, 159.0, 
162.6, 164.3 and 187.1; IR (nujol) 3300 and 1680cm-1; HRMS calcd. 
380.1498, found 380.1517. 
C22H22NOs 
4.2.8. 2-( 4-Methoxybenzoyl)-3,4-di-(4' -methoxyphenyl)pyrrole (11) 
This compound was prepared in a manner analogous to compound 7. The 
purified product exhibited the following properties: m.p. 77-79 °C; 
1H NMR (CDC13) 6 3.70 (s, 3 H), 3.72 (s, 3 H), 3.78 (s, 3 H), 6.52 
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(d,J=8.8Hz, 2H), 6.54 (d, J=8.8Hz, 2H), 6.75 (d, J=8.8Hz, 2H)
6.80 (d, J=8.8Hz, 2H), 7.00 (d, J=8.8Hz, 2H), 7.15 (d, J=2.9Hz,
I H), 7.40 (d, J = 8.8 Hz, 2H) and 9.45 (broads, 1 H); 13C NMR (CDCh) 
6 55.3, 55.4, 113.0, 113.5, 113.8, 113.9, 122.0, 127.0, 127.4, 129.3,
129.6, 129.9, 130.6, 131.7, 132.6, 158.4, 158.6, 162.3 and 186.7; IR (KBr)
3350 and 1600 cm-1; HRMS (EI) calcd. 414.1705, found 414.1693. 
C26H24N04 
4.3. Pharmacological studies 
4.3. I. Cytotoxicity 
Compounds 1 and 11 (Table 1) were tested for cytotoxic activity by homo-
genizing the drugs as a I mM solution in 0.05% Tween" 80/water. These 
solutions were sterilized by passing them through an acrodisc (0.45 µm). 
The following cell lines were maintained by literature techniques (8]: muri-
ne L1210 lymphoid leukemia and P388 lymphocytic leukemia, human 
Tmol4 and Tmolt3 acute lymphoblastic T cell leukemia, Hl-60 leukemia, 
Hut-78 cutaneous lymphoma, THP-1 monocytic leukemia, SW480 colorec-
tal adenocarcinoma, HCT-8 ileocecal adenocarcinoma, MB-9812 lung 
bronchogenic, A-549 lung carcinoma, TE-418 osteosarcoma, KB epider-
moid nasopharynx, HeLa-S3 suspended and HeLa solid cervical carcinoma, 
Sk-MEL-2 malignant melanoma and U-87-MG glioma. The NCI protocol 
was used to assess the cytotoxicity of the test compounds and standards in 
each cell line. Values for cytotoxicity were expressed as ED50 = µg/ml, i.e. 
the concentration of the compound inhibiting 50% of cell growth. ED50 
values were determined by the trypan blue exclusion technique [17]. A 
value of less than 4 µg/ml was required for significant activity of growth 
inhibition. Solid tumor cytotoxicity was determined utilizing crystal violet/ 
MeOH and read at 580 nm (Molecular Devices) [9]. 
4.3.2. Incorporation studies 
Incorporation of labeled precursors into 3H-DNA, 3H-RNA and 3H-protein 
for I 06 Tmol4 leukemia cells was obtained [I OJ using a concentration 
range of 25, 50 and 100 µM of the test agents over a 60 min incubations. 
The incorporation of 14C-glycine (53.0 mCi/mmol) into purines (11] and 
the incorporation of 14C-formate (53.0 mCi/mmol) into pyrimidines (12) 
was determined in a similar manner. 
4.3.3. Enzyme assays 
Inhibition of various enzyme activities was performed by first preparing 
the appropriate Tmol4 leukemia cell homogenates or subcellular fractions, 
then adding the drug to be tested during the enzyme assay. For the concen-
tration response studies, inhibition of enzyme activity was determined at 
25, 50 and 100 µM of compounds 9, 10 and 11, after 60 min incubations. 
DNA polymerase a activity was determined in cytoplasmic isolated ex-
tracts [13]. Nuclear DNA polymerase ~was determined by isolating nuclei 
[14]. The polymerase assay for both a and~ was determined with 3H-TIP 
(15]. Messenger-, ribosomal- and transfer-RNA polymerase enzymes were 
isolated with different concentrations of ammonium sulfate; individual 
RNA polymerase activities were determined using 3H-UTP [16, 17]. Ribo-
nucleoside reductase activity was measured using 14C-CDP with dithioery-
thritol [18]. The deoxyribonucleotides 14C-dCDP were separated from the 
ribonucleotides by TLC on PEI plates. Thymidine, TMP and TOP kinase 
activities were determined using 3H-thymidine (58.3 mCi/mmol) [19]. Carb-
amyl phosphate synthetase activity was determined [20] with citrulline 
quanititated colorimetrically (21]. Aspartate transcarbamylase activity was 
measured (20] and carbamyl aspartate was quanititated colorimetrically 
(22]. Thymidylate synthetase activity was analyzed by the 3H20 released 
which was proportional to the amount of TMP formed from 3H-dUMP 
(23]. Dihydrofolate reductase activity was determined by a spectrophoto-
metric method (24]. PRPP amidotransferase activity was determined by the 
method of Spassova et al. [25]. IMP dehydrogenase activity was analyzed 
with 8-'4C-IMP (54 mCi/mmol) (Amersham, Arlington Heights, IL) after 
separating XMP on PEI plates (Fisher Scientific) by TLC (26]. Protein 
content was determined for the enzymatic assays by the Lowry et al. tech-
nique (27]. 
4.3.4. ct-DNA studies 
After deoxyribonucleoside triphosphates were extracted (28], levels were 
determined by the method of Hunting and Henderson [29] with calf thy-
mus DNA, E. coli DNA polymerase I, non-limiting amounts of the three 
deoxyribonucleoside triphosphates not being assayed, and either 0.4 mCi 
of (3H-methyl)-dTTP or (5-3H)-dCTP. The effects of compounds 9, 10 and 
11 on DNA strand scission was determined by the methods of Suzuki et 
al. (31], Pera et al. [30] and Woynarowski et al. (32]. Tmol4 leukemia 
cells were incubated with 10 µCi thymidine (methyl-3H, 84.0 Ci/mmol] for 
24 h at 37 °C. Ll210 cells (107) were harvested and then centrifuged at 
600 x g for 10 min in PBS. They were later washed and suspended in 
I ml of PBS. Lysis buffer (0.5 ml; 0.5 M sodium hydroxide, 0.02 M 
EDTA, 0.01% Triton X-100 and 2.5% sucrose) was layered onto a 5-20% 
alkaline-sucrose gradient (5 ml; 0.3 M sodium hydroxide, 0.7M potassium 
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chloride and 0.01 M EDTA); this was followed by 0.2 ml of the cell pre-
paration. After the gradient was incubated for 2.5 h at room temperature, it 
was centrifuged at 12,000 RPM at 20 °C for 60 min (Beckman rotor 
SW60). Fractions (0.2 ml) were collected from the bottom of the gradient, 
neutralized with 0.2 ml of 0.3 N hydrochloric acid and measured for radio-
activity. Thermal calf thymus DNA denaturation studies, DNA UV absorp-
tion studies and DNA viscosity studies were conducted after incubation of 
compounds 9, 10 and 11 at 100 µMat 37 °C for 24 h [33]. 
4.3.5. Statistical analysis 
Data is displayed in Tables and the Fig. as the means ± standard devia-
tions of the mean. N is the number of samples or animals per group. The 
Student's "t" -test was used to determine the probable level of significance 
(p) between test samples and control samples. 
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